Kohrt HE - Search Results

1

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW. Liu J, et al. Among authors: kohrt he. Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8. Cancer Res. 2016. PMID: 27503925

2

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Souza-Fonseca-Guimaraes F, Blake SJ, Makkouk A, Chester C, Kohrt HE, Smyth MJ. Souza-Fonseca-Guimaraes F, et al. Among authors: kohrt he. Oncoimmunology. 2016 Jun 30;5(7):e1192740. doi: 10.1080/2162402X.2016.1192740. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622048 Free PMC article.

3

Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.

Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, Levy R. Goldstein MJ, et al. Among authors: kohrt he. Cancer Res. 2012 Mar 1;72(5):1239-47. doi: 10.1158/0008-5472.CAN-11-3375. Epub 2012 Jan 9. Cancer Res. 2012. PMID: 22232735 Free PMC article.

4

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Yonezawa A, et al. Among authors: kohrt he. Clin Cancer Res. 2015 Jul 15;21(14):3113-20. doi: 10.1158/1078-0432.CCR-15-0263. Epub 2015 Apr 23. Clin Cancer Res. 2015. PMID: 25908780 Free PMC article. Review.

5

Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S. Filatenkov A, et al. Radiat Res. 2014 Aug;182(2):163-9. doi: 10.1667/RR13471.1. Epub 2014 Jul 3. Radiat Res. 2014. PMID: 24992165 Free PMC article.

6

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Sanmamed MF, Chester C, Melero I, Kohrt H. Sanmamed MF, et al. Ann Oncol. 2016 Jul;27(7):1190-8. doi: 10.1093/annonc/mdw041. Epub 2016 Feb 23. Ann Oncol. 2016. PMID: 26912558 Free article. Review.

7

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Houot R, Schultz LM, Marabelle A, Kohrt H. Houot R, et al. Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190. Cancer Immunol Res. 2015. PMID: 26438444 Review.

8

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Marabelle A, et al. J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859. J Clin Invest. 2013. PMID: 23728179 Free PMC article.

9

Intratumoral immunization: a new paradigm for cancer therapy.

Marabelle A, Kohrt H, Caux C, Levy R. Marabelle A, et al. Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116. Clin Cancer Res. 2014. PMID: 24691639 Free PMC article.

10

Rationale for anti-CD137 cancer immunotherapy.

Makkouk A, Chester C, Kohrt HE. Makkouk A, et al. Among authors: kohrt he. Eur J Cancer. 2016 Feb;54:112-119. doi: 10.1016/j.ejca.2015.09.026. Epub 2016 Jan 2. Eur J Cancer. 2016. PMID: 26751393 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

119 results

Search Page

Filters